

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)


Sheet No.	1	of	2
-----------	---	----	---

Complete If Known

Complete if Known	
Application Number	101662,820
Filing Date	September 16, 2003
First Named Inventor	Koike et al.
Att. Unit	To Be Assigned 1614
Examiner Name	To Be Assigned HEW157
Attorney Docket Number	1089.0410001/1UM

[illegible]

FOREIGN PATENT DOCUMENTS

Examine r Initial s*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T o
		Country Code* Kind Code* (In known)				
	AA1	JP 06-305955	11-01-1994	Eisai Co. Ltd.		
	AB1	JP 63-185921 A	08-01-1988	Takeda Chem Ind. Ltd.		

Examiner Signature

Date Considered

11/12/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Offices that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/662,820
				Filing Date	September 16, 2003
				First Named Inventor	Koike et al.
				Art Unit	To Be Assigned 1614
				Examiner Name	To Be Assigned HENLEY
Sheet	2	Of	2	Attorney Docket Number	1089.0410001/TUM

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T‡
[Signature]	AA2	"Comparison of Antitumor Activity of Vitamins K ₁ , K ₂ and K ₃ on Human Tumor Cells By Two (MTT and SRB) Cell Viability Assays," Felicia Y. - H. Wu et al., Life Sciences, Vol. 52 pp. 1797-1804, Pergamon Press 1993.	
	AB2	"Changes of Plasma Des-y-Carboxy Prothrombin Levels In Patients With Hepatocellular Carcinoma In Response to Vitamin K," Midori Furukawa et al., Cancer, Vol. 69, Number 1, pp. 31-38, J.B. Lippincott Company, Philadelphia, January 1, 1992.	
	AC2	"DES-y-Carboxy Prothrombin As A Useful Predisposing Factor for the Development of Portal Venous Invasion in Patients with Hepatocellular Carcinoma," Yukihiro Koike et al., Cancer, Vol. 91, Number 3, pp. 561-569, John Wiley & Sons, Inc., February 1, 2001.	
	AD2	"The Growth Inhibitory Effects of Vitamins K and Their Actions On Gene Expression," Ziqiu Wang et al., Hepatology, Vol. 22, pp. 876-882, September 1995.	
[Signature]	AE2	O'Neil, J.M. et al., The Merck Index Thirteenth Edition, Merck & Co., Inc., 2001 pg. 1787, Item 10082 on Vitamin K.	
	AF2	Randomized Prospective Study of Prevention from Tumor Invasion Into Portal Vein In 120 Patients with Hepatocellular Carcinoma by Vitamin K Administration, http://ddw02.agora.com/planner/displayabstract.asp?presentationid=31, July 8, 2002.	
[Signature]	AG2	38 th Annual Meeting of Liver Cancer Study Group of Japan, Item 110, p. 135, Inhibitory Effect of Vitamin K Injection Against the Recurrence of Hepatocellular Carcinoma, published on May 13, 2002	✓
	AH2	Japanese Journal of Gastroenterology, Vol. 99 Supplement, March 20, 2002, Item 308, A Clinical Study of the Effects of Vitamin K in Inhibiting Recurrence of Hepatocellular Carcinoma	✓
[Signature]	AI2	ACTA Hepatologica Japonica, Vol. 43 Supplement (I) 2002, May 20, 2003, Item O-98, A Randomized Prospective Controlled Study by Vitamin K-II Injection for the Purpose of Preventing Portal Venous Invasion (PVI)	✓

Examiner Signature	[Signature]	Date Considered	11/12/04
--------------------	-------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 †Applicant's unique citation designation number (optional). ‡Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9198 and select option 2.

PTO/SB/08B (08-04)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE